Loading...

BioTelemetry

Nasdaq:BEAT
Snowflake Description

Moderate growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BEAT
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • BioTelemetry has significant price volatility in the past 3 months.
BEAT Share Price and Events
7 Day Returns
3.5%
NasdaqGS:BEAT
0.8%
US Healthcare
1.2%
US Market
1 Year Returns
11.4%
NasdaqGS:BEAT
-2.8%
US Healthcare
2.3%
US Market
BEAT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioTelemetry (BEAT) 3.5% 2.8% -19.5% 11.4% 224.7% 587.1%
US Healthcare 0.8% 3.5% -0.9% -2.8% 23.6% 63.1%
US Market 1.2% 2% 2% 2.3% 37.9% 39.8%
1 Year Return vs Industry and Market
  • BEAT outperformed the Healthcare industry which returned -2.8% over the past year.
  • BEAT outperformed the Market in United States of America which returned 2.3% over the past year.
Price Volatility
BEAT
Industry
5yr Volatility vs Market

Value

 Is BioTelemetry undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioTelemetry to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioTelemetry.

NasdaqGS:BEAT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:BEAT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.639 (1 + (1- 21%) (12.71%))
0.801
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.801 * 5.96%)
7.5%

Discounted Cash Flow Calculation for NasdaqGS:BEAT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioTelemetry is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:BEAT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 84.16 Analyst x2 78.29
2020 97.37 Analyst x2 84.25
2021 105.30 Analyst x1 84.75
2022 131.00 Analyst x1 98.08
2023 156.60 Analyst x1 109.06
2024 176.08 Est @ 12.44% 114.06
2025 192.86 Est @ 9.53% 116.21
2026 207.30 Est @ 7.49% 116.19
2027 219.87 Est @ 6.06% 114.63
2028 231.00 Est @ 5.06% 112.03
Present value of next 10 years cash flows $1,027.55
NasdaqGS:BEAT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $231.00 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$4,969.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,969.85 ÷ (1 + 7.5%)10
$2,410.25
NasdaqGS:BEAT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,027.55 + $2,410.25
$3,437.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,437.80 / 33.80
$101.7
NasdaqGS:BEAT Discount to Share Price
Calculation Result
Value per share (USD) From above. $101.70
Current discount Discount to share price of $51.60
= -1 x ($51.60 - $101.70) / $101.70
49.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BioTelemetry is available for.
Intrinsic value
49%
Share price is $51.6 vs Future cash flow value of $101.7
Current Discount Checks
For BioTelemetry to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BioTelemetry's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BioTelemetry's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioTelemetry's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioTelemetry's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:BEAT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $1.47
NasdaqGS:BEAT Share Price ** NasdaqGS (2019-06-19) in USD $51.6
United States of America Healthcare Industry PE Ratio Median Figure of 57 Publicly-Listed Healthcare Companies 20.87x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioTelemetry.

NasdaqGS:BEAT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BEAT Share Price ÷ EPS (both in USD)

= 51.6 ÷ 1.47

35.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioTelemetry is overvalued based on earnings compared to the US Healthcare industry average.
  • BioTelemetry is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does BioTelemetry's expected growth come at a high price?
Raw Data
NasdaqGS:BEAT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 35.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
14%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 43 Publicly-Listed Healthcare Companies 1.65x
United States of America Market PEG Ratio Median Figure of 2,128 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

NasdaqGS:BEAT PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 35.07x ÷ 14%

2.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioTelemetry is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on BioTelemetry's assets?
Raw Data
NasdaqGS:BEAT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $9.85
NasdaqGS:BEAT Share Price * NasdaqGS (2019-06-19) in USD $51.6
United States of America Healthcare Industry PB Ratio Median Figure of 93 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,246 Publicly-Listed Companies 1.8x
NasdaqGS:BEAT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BEAT Share Price ÷ Book Value per Share (both in USD)

= 51.6 ÷ 9.85

5.24x

* Primary Listing of BioTelemetry.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioTelemetry is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess BioTelemetry's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. BioTelemetry has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioTelemetry expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioTelemetry expected to grow at an attractive rate?
  • BioTelemetry's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • BioTelemetry's earnings growth is expected to exceed the United States of America market average.
  • BioTelemetry's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:BEAT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:BEAT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 14%
NasdaqGS:BEAT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 12.2%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:BEAT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:BEAT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 725 1
2022-12-31 636 1
2021-12-31 561 1
2020-12-31 496 132 61 6
2019-12-31 447 120 54 6
NasdaqGS:BEAT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 386 81 49
2018-12-31 377 73 43
2018-09-30 366 57 17
2018-06-30 349 29 -1
2018-03-31 310 28 -10
2017-12-31 273 24 -16
2017-09-30 238 23 40
2017-06-30 211 32 47
2017-03-31 205 35 50
2016-12-31 198 39 53
2016-09-30 192 34 16
2016-06-30 183 29 14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioTelemetry's earnings are expected to grow by 14% yearly, however this is not considered high growth (20% yearly).
  • BioTelemetry's revenue is expected to grow by 12.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:BEAT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from BioTelemetry Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BEAT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 1.65 1.90 1.46 6.00
2019-12-31 1.46 1.60 1.36 6.00
NasdaqGS:BEAT Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 1.47
2018-12-31 1.31
2018-09-30 0.52
2018-06-30 -0.05
2018-03-31 -0.32
2017-12-31 -0.53
2017-09-30 1.37
2017-06-30 1.64
2017-03-31 1.76
2016-12-31 1.91
2016-09-30 0.57
2016-06-30 0.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioTelemetry will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioTelemetry's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioTelemetry has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioTelemetry performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioTelemetry's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioTelemetry has delivered over 20% year on year earnings growth in the past 5 years.
  • BioTelemetry has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • BioTelemetry has become profitable in the last year making it difficult to compare the US Healthcare industry average.
Earnings and Revenue History
BioTelemetry's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioTelemetry Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BEAT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 386.46 48.52 154.57 11.25
2018-12-31 377.25 42.82 152.59 11.21
2018-09-30 366.39 16.83 151.97 11.33
2018-06-30 348.78 -1.45 150.57 12.18
2018-03-31 310.01 -10.17 132.75 11.96
2017-12-31 273.49 -15.96 118.31 11.10
2017-09-30 237.88 40.09 102.90 10.69
2017-06-30 211.19 46.57 88.74 9.55
2017-03-31 205.49 49.54 88.25 9.00
2016-12-31 198.40 53.44 84.51 8.36
2016-09-30 192.07 15.84 82.24 7.84
2016-06-30 182.76 14.12 79.50 7.27
2016-03-31 175.38 11.59 77.12 6.93
2015-12-31 170.47 7.43 75.82 7.11
2015-09-30 166.25 2.93 74.97 6.82
2015-06-30 166.25 0.42 75.13 7.25
2015-03-31 163.51 -5.74 74.30 7.57
2014-12-31 157.23 -9.79 73.94 7.40
2014-09-30 147.13 -8.12 70.35 7.68
2014-06-30 136.33 -11.04 67.73 7.58
2014-03-31 126.57 -9.35 64.77 7.51
2013-12-31 121.71 -7.32 62.84 7.34
2013-09-30 117.65 -11.69 62.02 6.70
2013-06-30 111.05 -11.86 60.80 5.94
2013-03-31 105.40 -10.76 59.11 5.10
2012-12-31 99.58 -12.20 58.25 4.66
2012-09-30 95.73 -57.61 56.37 4.69
2012-06-30 95.22 -61.60 57.20 4.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BioTelemetry has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • BioTelemetry used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
  • BioTelemetry's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BioTelemetry's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioTelemetry has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioTelemetry's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioTelemetry's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioTelemetry is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioTelemetry's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of BioTelemetry's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioTelemetry Company Filings, last reported 2 months ago.

NasdaqGS:BEAT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 333.01 221.74 45.49
2018-12-31 310.49 200.32 80.89
2018-09-30 295.52 201.26 63.12
2018-06-30 273.20 202.49 39.43
2018-03-31 256.35 203.70 36.35
2017-12-31 249.70 204.87 36.02
2017-09-30 268.31 206.57 26.24
2017-06-30 146.78 24.80 26.90
2017-03-31 142.91 25.13 25.10
2016-12-31 138.91 25.45 23.05
2016-09-30 95.03 37.41 32.26
2016-06-30 88.50 37.76 25.44
2016-03-31 80.66 23.24 22.84
2015-12-31 75.93 23.58 18.99
2015-09-30 71.45 24.02 15.49
2015-06-30 67.25 24.39 14.80
2015-03-31 64.05 24.79 12.29
2014-12-31 63.68 24.74 20.01
2014-09-30 63.92 18.53 12.19
2014-06-30 62.70 18.78 13.55
2014-03-31 64.77 11.12 12.04
2013-12-31 66.83 0.66 22.15
2013-09-30 65.75 0.70 21.02
2013-06-30 67.59 0.00 19.31
2013-03-31 68.82 0.00 18.32
2012-12-31 70.00 0.00 18.30
2012-09-30 73.26 0.00 17.89
2012-06-30 75.35 0.00 34.13
  • BioTelemetry's level of debt (59.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (17.3% vs 59.8% today).
  • Debt is well covered by operating cash flow (40.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 7x coverage).
X
Financial health checks
We assess BioTelemetry's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioTelemetry has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioTelemetry's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioTelemetry dividends.
If you bought $2,000 of BioTelemetry shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioTelemetry's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioTelemetry's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:BEAT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:BEAT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioTelemetry has not reported any payouts.
  • Unable to verify if BioTelemetry's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioTelemetry's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioTelemetry has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioTelemetry's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioTelemetry afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioTelemetry has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioTelemetry's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Capper
COMPENSATION $3,875,558
AGE 54
TENURE AS CEO 9 years
CEO Bio

Mr. Joseph H. Capper, also known as Joe, has been the Chief Executive Officer and President at BioTelemetry, Inc. formerly known as CardioNet, Inc. since June 2010. Mr. Capper served as the Chief Executive Officer at Trividia Health, Inc. (Also known as Home Diagnostics Inc.) since February 2009 and served as its President from February 2009 to July 2010. He has over 17 years of executive management experience. He joined Home Diagnostics, Inc. in 2009 and positioned it for a strategic merger in a transaction that created ubstantial value to its stakeholders. He served as the Chief Executive Officer of CCS Medical Holdings, Inc. from September 2003 to 2008 and as its President from March 2003 to 2008. He was responsible for acquiring and integrating Becton Dickenson's blood glucose monitoring division into CCS product line and commercializing it under the Nova Max brand. Prior to joining CCS, he worked with Bayer Healthcare's diabetes care division, where he served as the division's National Sales Director and he led a 180 person sales organization with responsibility for over $350 million in revenue. He joined CCS Medical in March 2003. He served as Director of Sales of Diagnostics Division at Bayer Corporation (focused on diabetes devices and ancillary products) from September 1994 to March 2003. He served for nine years as a U.S. Naval Officer, where he served as a combat-decorated Naval Flight Officer, served as a Staff Officer assigned to Joint Chiefs of Staff, as a Combat Aviator and as a Congressional Liaison Officer supporting congressional committees. He has been a Director of VirtualScopics, Inc. since May 11, 2016 and BioTelemetry, Inc. since June 2010. He has been a Director of LifeWatch AG since July 21, 2017. He served as a Director of CCS Medical Holdings, Inc. He served as a Director of Trividia Health, Inc. since February 2009. Mr. Capper holds a Bachelor of Science in Accounting from West Chester University and an M.B.A. in International Finance from George Washington University.

CEO Compensation
  • Joe's compensation has increased in line with BioTelemetry recently becoming profitable.
  • Joe's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioTelemetry management team in years:

8.4
Average Tenure
49
Average Age
  • The average tenure for the BioTelemetry management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Joe Capper

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
54
TENURE
9 yrs

Heather Getz

TITLE
Executive VP & CFO
COMPENSATION
$2M
AGE
43
TENURE
9.4 yrs

Peter Ferola

TITLE
Senior VP
COMPENSATION
$918K
AGE
49
TENURE
8.3 yrs

Andy Broadway

TITLE
President of BioTel Heart
COMPENSATION
$1M
AGE
48
TENURE
1.4 yrs

Dan Wisniewski

TITLE
Senior Vice President of Technical Operations
COMPENSATION
$935K
AGE
54
TENURE
8.5 yrs

Tim Raher

TITLE
Senior Vice President of Human Resources
TENURE
1.9 yrs

Peter Kowey

TITLE
Medical Director and Chairman of Medical Advisory Board
TENURE
17.4 yrs

Wayne Derkac

TITLE
Senior VP of Medical Affairs
TENURE
0.4 yrs

Scott Satin

TITLE
President & General Manager of BioTel Research
Board of Directors Tenure

Average tenure and age of the BioTelemetry board of directors in years:

10.1
Average Tenure
67
Average Age
  • The average tenure for the BioTelemetry board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Kirk Gorman

TITLE
Chairman
COMPENSATION
$231K
AGE
67
TENURE
7.7 yrs

Joe Capper

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
54
TENURE
9 yrs

Peter Kowey

TITLE
Medical Director and Chairman of Medical Advisory Board
TENURE
10.3 yrs

Rebecca Rimel

TITLE
Director
COMPENSATION
$205K
AGE
67
TENURE
10.1 yrs

Tony Conti

TITLE
Director
COMPENSATION
$203K
AGE
69
TENURE
7.1 yrs

Joe Frick

TITLE
Independent Director
COMPENSATION
$202K
AGE
65
TENURE
5.7 yrs

David Benditt

TITLE
Member of Medical Advisory Board
AGE
71

Robert Rubin

TITLE
Director
COMPENSATION
$199K
AGE
72
TENURE
11.9 yrs

Arthur Moss

TITLE
Member of Medical Advisory Board
TENURE
10.3 yrs

Kenneth Ellenbogen

TITLE
Member of Medical Advisory Board
TENURE
10.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess BioTelemetry's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioTelemetry has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What BioTelemetry, Inc.'s (NASDAQ:BEAT) ROE Can Tell Us

One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.15 in profit. … The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for BioTelemetry: 15% = US$49m ÷ US$333m (Based on the trailing twelve months to March 2019.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … BioTelemetry's Debt And Its 15% ROE Although BioTelemetry does use debt, its debt to equity ratio of 0.67 is still low.

Simply Wall St -

Is BioTelemetry, Inc. (NASDAQ:BEAT) Trading At A 41% Discount?

by estimating the company's future cash flows and discounting them to their present value. … We generally believe that a company's value is the present value of all of the cash it will generate in the future. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

What Investors Should Know About BioTelemetry, Inc.'s (NASDAQ:BEAT) Financial Strength

However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is. … Let's work through some financial health checks you may wish to consider if you're interested in this stock.

Simply Wall St -

Should You Worry About BioTelemetry, Inc.'s (NASDAQ:BEAT) CEO Pay?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Joe Capper's Compensation Compare With Similar Sized Companies. … has a market cap of US$2.0b, and is paying total annual CEO compensation of US$3.9m.

Simply Wall St -

Why BioTelemetry, Inc. (NASDAQ:BEAT) Could Be Worth Watching

As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock? … However, could the stock still be trading at a relatively cheap price. … Let’s take a look at BioTelemetry’s outlook and value based on the most recent financial data to see if the opportunity still exists

Simply Wall St -

BioTelemetry, Inc. (NASDAQ:BEAT): Time For A Financial Health Check

BEAT’s financial liquidity and debt position will be analysed in this article, to get an idea of whether the company can fund opportunities for strategic growth and maintain strength through economic downturns. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … Does BEAT produce enough cash relative to debt?

Simply Wall St -

A Closer Look At BioTelemetry, Inc.'s (NASDAQ:BEAT) Uninspiring ROE

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.051 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is BioTelemetry, Inc. (NASDAQ:BEAT) Worth US$67.87 Based On Intrinsic Value?

Today, I will calculate the stock's intrinsic value. … by taking the foreast future cash flows of the company and discounting them back to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Should You Worry About BioTelemetry, Inc.’s (NASDAQ:BEAT) ROCE?

To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … First up, we'll look at what ROCE is and how we calculate it. … Understanding Return On Capital Employed (ROCE).

Simply Wall St -

Is BioTelemetry, Inc.'s (NASDAQ:BEAT) CEO Paid Enough Relative To Peers?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Joe Capper's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$2.0b, and pays its CEO total annual compensation worth US$2.7m.

Simply Wall St -

Company Info

Description

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and INR monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Corporate and Other segment focuses on the manufacture, engineering, development, and sale of non-invasive cardiac monitors and other population health management devices for healthcare companies, as well as contract manufacturing services under the BioTel Care and BioTel Alliance names. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania.

Details
Name: BioTelemetry, Inc.
BEAT
Exchange: NasdaqGS
Founded: 1994
$1,744,272,777
33,803,736
Website: http://www.gobio.com
Address: BioTelemetry, Inc.
1000 Cedar Hollow Road,
Suite 102,
Malvern,
Pennsylvania, 19355,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BEAT Common Stock Nasdaq Global Select US USD 19. Mar 2008
DB C25 Common Stock Deutsche Boerse AG DE EUR 19. Mar 2008
LSE 0HNH Common Stock London Stock Exchange GB USD 19. Mar 2008
Number of employees
Current staff
Staff numbers
1,500
BioTelemetry employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/20 00:16
End of day share price update: 2019/06/19 00:00
Last estimates confirmation: 2019/06/07
Last earnings filing: 2019/04/25
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.